Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults
Open Access
- 12 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 76 (3), 485-490
- https://doi.org/10.1093/gerona/glaa127
Abstract
Herpes zoster may significantly impact quality of life (QoL) in older adults. The recombinant zoster vaccine (RZV) is efficacious in adults aged ≥50 and older and is associated with increased reactogenicity compared to placebo. We report here on the impact of reactogenicity of the second RZV dose on the QoL and physical functioning (PF) of vaccine recipients, and summarize findings following both doses. In this single-arm study, 401 adults aged ≥50 and older were enrolled to receive two RZV doses 2 months apart. Change in mean Short Form Survey-36 (SF-36) PF and EuroQol-5 Dimension (EQ-5D) scores, reactogenicity, safety, productivity loss, and healthcare resource utilization were evaluated. In total, 391 (97.5%) participants received dose 2. Post-dose 2, the most common solicited local symptoms were injection site pain (75.1%), erythema (22.4%), and swelling (13.9%), and the most common systemic symptoms were fatigue (46.3%), headache (37.5%), and myalgia (32.9%). Grade 3 solicited (local and systemic) adverse events were reported by 61 (15.6%) participants and were associated with a transient clinically significant decrease in SF-36 PF score on Days 1–2 post-dose 2 that recovered by Day 3. Overall, no clinically important reduction in mean SF-36 PF scores was observed from baseline to post-dose 2 (mean change −0.4), and no quality-adjusted-life-year loss was recorded. Overall, QoL and PF of RZV vaccinees were not affected by vaccine-related reactogenicity. A transient reduction was observed in the first 2 days after RZV vaccination in individuals with Grade 3 adverse events. No safety concerns were identified.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA
- National Institute on Aging (P30AG028716)
This publication has 26 references indexed in Scilit:
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsThe New England Journal of Medicine, 2015
- The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical reviewBMC Public Health, 2015
- Quantification of risk factors for herpes zoster: population based case-control studyBMJ, 2014
- Herpes ZosterThe New England Journal of Medicine, 2013
- Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective studyVaccine, 2012
- Work and productivity loss related to herpes zosterJournal of Medical Economics, 2011
- A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UKCost Effectiveness and Resource Allocation, 2010
- Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health PlansPharmacoEconomics, 2009
- Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adultsVaccine, 2007
- The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older AdultsThe Clinical Journal of Pain, 2007